IDH2 and central nervous system cancer: The predominant IDH mutation, IDH1R132H, is common in low-grade gliomas (>70%) and ‘secondary’ glioblastomas (>80%, astrocytoma grade 4), but rare in ‘primary’ glioblastoma (12%) (2, 4).